Search
for
Sort by
Research 91–120 of 110
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Folliculotropic Mycosis Fungoides: Update on Diagnosis, Clinicopathological Stage, and Management
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
- Cancer-Related Alopecia Risk and Treatment
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Breast cancer in a transgender man
- Effectiveness and Safety Profile of Cisplatin Versus Nab-Paclitaxel Concomitant Chemoradiotherapy in Postoperative Early-Stage Cancer of Cervix
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
- Persistent Gynecomastia due to Short-term Low-dose Finasteride for Androgenetic Alopecia
- Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
- Millets as a dietary supplement for managing chemotherapy induced side effects
- E-Poster
- Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software
- Synthetic Approaches for Pharmacologically Active Decorated Six-Membered Diazines
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Subject Index
- ZALCITABINE
- Scalp hypothermia as a preventative measure for chemotherapy‐induced alopecia: a review of controlled clinical trials
- High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
- [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Alopecia and Hair Damage Induced by Oncological Therapy
- Reporting on Adverse Clinical Events
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Efluvio anágeno. Hallazgos tricoscópicos